Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer, Metastatic Cholangiocarcinoma and Metastatic Esophageal Clinical Trial Using Fludarabine, Aldesleukin, CD8+ young TIL and Cyclophosphamide

- The folks at National Institutes of Health Clinical Center (CC) are studying the effects of CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine on Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer, Metastatic Cholangiocarcinoma and Metastatic Esophageal in individuals ages 18 years to 66 years. This clinical trial is slated to start July 2010 and is expected to end circa July 2015.

(301) 451-1929
June Kryk, R.N.
Overall Study Contact Info
StatusName Contact Phone
RecruitingJune Kryk, R.N.ncisbirc@mail.nih.gov(301) 451-1929

This study is officially titled, "A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers."

Locations

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.